Sudarshan Pharma Industries Limited (BOM:543828)
India · Delayed Price · Currency is INR 31.00
+0.01 (0.03%)
At close: May 5, 2026
BOM:543828 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 7,031 | 5,050 | 4,635 | 4,613 | 3,571 |
Other Revenue | 87.13 | - | - | - | - |
| 7,118 | 5,050 | 4,635 | 4,613 | 3,571 | |
Revenue Growth (YoY) | 40.93% | 8.95% | 0.48% | 29.19% | 84.52% |
Cost of Revenue | 6,194 | 4,398 | 4,226 | 4,310 | 3,354 |
Gross Profit | 923.92 | 652.05 | 409.86 | 303.72 | 217.06 |
Selling, General & Admin | 74.37 | 70.27 | 47.49 | 41.93 | 30.82 |
Other Operating Expenses | 249.26 | 175.32 | 125.44 | 109.59 | 76.08 |
Operating Expenses | 361.52 | 267.8 | 185.38 | 160.59 | 115.56 |
Operating Income | 562.4 | 384.25 | 224.48 | 143.12 | 101.5 |
Interest Expense | -257.01 | -141.04 | -78.7 | -45.86 | -27.58 |
Interest & Investment Income | - | 5.55 | 7.88 | 4.9 | 1.99 |
Currency Exchange Gain (Loss) | - | 2.01 | 1.95 | 0.13 | 0.11 |
Other Non Operating Income (Expenses) | 0 | -6.3 | -3.33 | -4.95 | -3.67 |
EBT Excluding Unusual Items | 305.4 | 244.47 | 152.28 | 97.34 | 72.35 |
Gain (Loss) on Sale of Assets | - | - | - | -2.37 | -0.99 |
Other Unusual Items | - | -28.17 | - | - | - |
Pretax Income | 305.4 | 216.29 | 152.28 | 94.96 | 71.36 |
Income Tax Expense | 71.68 | 56.77 | 37.73 | 24.6 | 18.87 |
Earnings From Continuing Operations | 233.72 | 159.53 | 114.55 | 70.37 | 52.49 |
Minority Interest in Earnings | -0.68 | 0.02 | - | - | -0.01 |
Net Income | 233.03 | 159.55 | 114.55 | 70.37 | 52.48 |
Net Income to Common | 233.03 | 159.55 | 114.55 | 70.37 | 52.48 |
Net Income Growth | 46.05% | 39.28% | 62.79% | 34.09% | 96.46% |
Shares Outstanding (Basic) | 240 | 242 | 239 | 241 | 144 |
Shares Outstanding (Diluted) | 240 | 242 | 239 | 241 | 144 |
Shares Change (YoY) | -0.62% | 1.30% | -0.83% | 66.88% | -5.63% |
EPS (Basic) | 0.97 | 0.66 | 0.48 | 0.29 | 0.36 |
EPS (Diluted) | 0.97 | 0.66 | 0.48 | 0.29 | 0.36 |
EPS Growth | 46.97% | 37.50% | 64.16% | -19.65% | 108.19% |
Free Cash Flow | -713.96 | 302.13 | 59.02 | -431.2 | -54.79 |
Free Cash Flow Per Share | -2.97 | 1.25 | 0.25 | -1.79 | -0.38 |
Dividend Per Share | - | - | - | 0.030 | - |
Gross Margin | 12.98% | 12.91% | 8.84% | 6.58% | 6.08% |
Operating Margin | 7.90% | 7.61% | 4.84% | 3.10% | 2.84% |
Profit Margin | 3.27% | 3.16% | 2.47% | 1.52% | 1.47% |
Free Cash Flow Margin | -10.03% | 5.98% | 1.27% | -9.35% | -1.53% |
EBITDA | 600.29 | 394.55 | 236.77 | 152.19 | 110.15 |
EBITDA Margin | 8.43% | 7.81% | 5.11% | 3.30% | 3.08% |
D&A For EBITDA | 37.88 | 10.3 | 12.29 | 9.07 | 8.66 |
EBIT | 562.4 | 384.25 | 224.48 | 143.12 | 101.5 |
EBIT Margin | 7.90% | 7.61% | 4.84% | 3.10% | 2.84% |
Effective Tax Rate | 23.47% | 26.24% | 24.78% | 25.90% | 26.45% |
Revenue as Reported | 7,118 | - | 4,661 | 4,624 | 3,576 |
Advertising Expenses | - | 0.21 | 0.28 | 0.07 | 0.04 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.